| | | |  | | | | By Lev Facher Jeff J Mitchell/Getty Images Endocarditis can require days of treatment in the hospital, and patients often face withdrawal symptoms at the same time. Read More | | By Bob Herman Baylor University Hospitals’ message at JPM23: This year will be about increasing revenue by expanding footprints and hiking prices. Read More | | By Daniel Eisenkraft Klein Adobe A House report blasted Biogen for putting profit over public interest with Aduhelm. It should have targeted the systems enabling its actions. Read More | | Sponsored Insight by Alnylam Pharmaceuticals How do genetic medicines based on RNA interference (RNAi) silence genes that cause diseases? During RNA translation, errors in DNA known as "mutations" result in faulty messenger RNA (mRNA) which cells use to produce proteins that cause or contribute to disease. RNAi therapeutics interfere with this process by targeting and destroying specific mRNA, treating disease at its source. Fortunately for patients, this innovative approach to treating disease is not hypothetical – it's a reality today, with several approved RNAi therapeutics available to treat both rare and more prevalent diseases, and more are on the way! Learn more about how RNAi therapeutics work. | | By Jason Mast Adobe CEO Steve Harr acknowledges setbacks but says Sana will start clinical trials of novel treatments for both cancer and diabetes this year. Read More | | By Katie Palmer Adobe Patients who got telehealth prescriptions for ADHD drugs and other controlled substances face challenges transitioning to in-person care. Read More | | By Ed Silverman Adobe A new analysis suggests patients still face significant barriers to access because of policy choices made by payers. Read More | | By Ed Silverman Adobe Pfizer's effort comes amid harsh criticism of the pharmaceutical industry for failing to do more to widen access to its products. Read More | |
No comments